Letters
Post-marketing surveillance should include effects during pregnancy
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7486.308-a (Published 03 February 2005) Cite this as: BMJ 2005;330:308
- Patricia Yeargin, associate medical editor, health promotions (yeargin2000@yahoo.com)
- American Cancer Society, 1599 Clifton Road, NE, Atlanta, GA 30329
EDITOR—I agree that post-marketing surveillance of drugs is desperately needed.1 I further believe that, since information about drugs' effects during human gestation is never studied during pre-marketing, some post-marketing study of fetal effects during pregnancy should be considered.
I have seen many women's medical care neglected during pregnancy owing to fear of harming the fetus, even when there is no real evidence …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.